EntryPoint Capital LLC Boosts Holdings in Cerus Co. (NASDAQ:CERS)

EntryPoint Capital LLC lifted its position in shares of Cerus Co. (NASDAQ:CERS) by 47.8% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 119,977 shares of the biotechnology company’s stock after buying an additional 38,777 shares during the period. EntryPoint Capital LLC’s holdings in Cerus were worth $185,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also recently made changes to their positions in the company. Bank of New York Mellon Corp increased its stake in Cerus by 1.2% during the fourth quarter. Bank of New York Mellon Corp now owns 485,797 shares of the biotechnology company’s stock worth $748,000 after acquiring an additional 5,721 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. grew its holdings in shares of Cerus by 3.3% during the 4th quarter. Connor Clark & Lunn Investment Management Ltd. now owns 209,246 shares of the biotechnology company’s stock worth $322,000 after purchasing an additional 6,633 shares during the period. Rhumbline Advisers increased its position in shares of Cerus by 3.7% during the 4th quarter. Rhumbline Advisers now owns 238,795 shares of the biotechnology company’s stock worth $368,000 after purchasing an additional 8,458 shares during the last quarter. Charles Schwab Investment Management Inc. raised its holdings in Cerus by 0.5% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,754,540 shares of the biotechnology company’s stock valued at $3,053,000 after buying an additional 8,707 shares during the period. Finally, Franklin Resources Inc. lifted its position in Cerus by 13.8% in the third quarter. Franklin Resources Inc. now owns 93,763 shares of the biotechnology company’s stock valued at $177,000 after buying an additional 11,338 shares during the last quarter. Hedge funds and other institutional investors own 78.37% of the company’s stock.

Cerus Trading Down 1.4 %

CERS opened at $1.42 on Friday. Cerus Co. has a 52 week low of $1.38 and a 52 week high of $2.54. The company has a quick ratio of 1.92, a current ratio of 2.59 and a debt-to-equity ratio of 1.19. The business has a fifty day simple moving average of $1.68 and a 200-day simple moving average of $1.72. The firm has a market cap of $263.82 million, a P/E ratio of -12.91 and a beta of 1.56.

Cerus (NASDAQ:CERS) last announced its earnings results on Thursday, February 20th. The biotechnology company reported ($0.01) EPS for the quarter, meeting analysts’ consensus estimates of ($0.01). The company had revenue of $50.81 million during the quarter, compared to analysts’ expectations of $50.81 million. Cerus had a negative return on equity of 40.55% and a negative net margin of 11.60%. On average, equities analysts expect that Cerus Co. will post -0.08 earnings per share for the current year.

Analyst Ratings Changes

Separately, Cantor Fitzgerald reiterated an “overweight” rating and set a $4.00 price target on shares of Cerus in a research report on Friday, February 21st.

Insider Activity

In other news, CEO William Mariner Greenman sold 23,023 shares of the company’s stock in a transaction on Tuesday, March 4th. The stock was sold at an average price of $1.55, for a total transaction of $35,685.65. Following the sale, the chief executive officer now owns 3,230,000 shares of the company’s stock, valued at approximately $5,006,500. This represents a 0.71 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Richard J. Benjamin sold 51,254 shares of Cerus stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $1.58, for a total value of $80,981.32. Following the completion of the transaction, the insider now owns 400,665 shares of the company’s stock, valued at approximately $633,050.70. This trade represents a 11.34 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 441,150 shares of company stock valued at $665,210. 3.40% of the stock is currently owned by company insiders.

Cerus Company Profile

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.